Short Interest in International Stem Cell Corp. (OTCMKTS:ISCO) Decreases By 51.1%

International Stem Cell Corp. (OTCMKTS:ISCO) was the recipient of a significant decline in short interest in the month of June. As of June 30th, there was short interest totaling 6,699 shares, a decline of 51.1% from the June 15th total of 13,705 shares. Based on an average daily trading volume, of 7,053 shares, the short-interest ratio is presently 0.9 days. Approximately 0.3% of the company’s shares are sold short.

International Stem Cell Stock Performance

Shares of ISCO stock remained flat at $0.17 during midday trading on Wednesday. The company’s stock had a trading volume of 7 shares, compared to its average volume of 5,746. The firm has a market cap of $1.32 million, a price-to-earnings ratio of -2.76 and a beta of -0.01. The company has a 50-day simple moving average of $0.17 and a 200 day simple moving average of $0.16. International Stem Cell has a 1 year low of $0.12 and a 1 year high of $0.27.

International Stem Cell (OTCMKTS:ISCO) last issued its quarterly earnings results on Thursday, May 14th. The biotechnology company reported ($0.03) earnings per share for the quarter. The firm had revenue of $2.32 million during the quarter.

About International Stem Cell

International Stem Cell Corporation (OTCMKTS:ISCO) is a biotechnology company focused on the development and commercialization of human parthenogenetic stem cells (hpSC) for therapeutic and research applications. Parthenogenetic stem cells are derived from unfertilized human eggs and offer a scalable, ethically noncontroversial source of pluripotent cells. ISCO’s proprietary hpSC lines can be directed to differentiate into a wide variety of cell types, enabling preclinical programs in areas such as neurodegenerative disease, liver disease, diabetes and corneal regeneration.

In addition to its therapeutic pipeline, International Stem Cell maintains a research products division that supplies hpSC lines, differentiated cell populations and media formulations to academic institutions, biotechnology companies and contract research organizations.